Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1].
in vivo
Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) decreases percentage of lymphocytes (Lym%) and increases percentage of neutrophils (Neu%)[1].
Animal Model:
WT and Masp2-/- (KO) mice (C57BL/6N, female, 12-15 weeks old)[1]
Dosage:
10 mg/kg
Administration:
Intravenous injection
Result:
Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%).
References
[1] Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318. DOI:10.1038/s41392-022-01133-5
